Evidence map›Paper›PMID 41376170›Full record

ArticleHGG advances2026

Lack of association between G6PD variants and Parkinson disease.

Leah V Chifamba, Sitki Cem Parlar, Lang Liu, Leonard L Sokol, Eric Yu, Farnaz Asayesh, Jamil Ahmad, Jennifer A Ruskey, Dan Spiegelman, Cheryl Waters and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Leah V ChifambaThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada.
Sitki Cem ParlarThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada.
Lang LiuThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada.
Leonard L SokolDepartment of Molecular Medicine and Division of Neurology, Department of Medicine, Scripps, La Jolla, CA, USA.
Eric YuThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada.
Farnaz AsayeshThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.
Jamil AhmadThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.
Jennifer A RuskeyThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.
Dan SpiegelmanThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada.
Cheryl WatersDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
Oury MonchiDepartment of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montréal, QC, Canada; Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montréal, QC, Canada.
Yves DauvilliersNational Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Guide-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France.
Nicolas DupréNeuroscience Axis, CHU de Québec-Université Laval, Québec, QC, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Alla TimofeevaPavlov First State Medical University of St. Petersburg, St. Petersburg, Russia.
Anton EmelyanovPavlov First State Medical University of St. Petersburg, St. Petersburg, Russia.
Sofya PchelinaPavlov First State Medical University of St. Petersburg, St. Petersburg, Russia.
Irina MiliukhinaInstitute of the Human Brain of RAS, St. Petersburg, Russia.
Lior GreenbaumDanek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Sharon Hassin-BaerTel Aviv School of Medicine, Tel Aviv University, Tel Aviv, Israel; Movement Disorders Institute, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
Roy N AlcalayDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Division of Movement Disorders, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Alberto J EspayJames J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
Ziv Gan-OrThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.
Konstantin SenkevichThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada. Electronic address: konstantin.senkevich@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress has been implicated in Parkinson disease (PD). Genes involved in PD, such as PRKN, PINK1, and PARK7, contribute to oxidative stress in dopaminergic neurons. The X-linked G6PD gene encodes glucose 6-phosphate dehydrogenase, an important regulator of oxidative stress. Recent studies suggested that alpha-synuclein aggregates may impair G6PD activity and contribute to dopaminergic neuron loss, and that G6PD mutations may independently increase the risk of PD. In this study, we aimed to examine the role of common and rare G6PD variants in PD across 6 cohorts, including 8,905 PD cases, 16,770 proxy cases, and 394,098 controls. These cohorts were analyzed after stratification by sex and then combined to account for the G6PD X-linked location. Using logistic regression, we did not identify significant associations for common variants in any of the cohorts. The optimized sequence Kernel association (SKAT-O) test was performed to assess the effect of rare variants (minor allele frequency <0.01) across six cohorts, followed by a meta-analysis using metaSKAT, also demonstrating lack of association. In conclusion, we did not find evidence for a role for G6PD in PD.

Indexed as

Genetic Predisposition to DiseaseGenetic VariationGlucosephosphate DehydrogenaseParkinson DiseaseAgedCase-Control StudiesFemaleGene FrequencyGenetic Association StudiesHumansMaleMiddle AgedPolymorphism, Single NucleotideG6PD protein, humanGlucosephosphate Dehydrogenasecommon variant associationG6PDoxidative stressParkinson’s diseaserare variant analysisSKAT-OX-linked genetics

Identifiers

PMID41376170
PMCPMC12799763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.